LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 55

Search options

  1. Article: Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy.

    Nair, Remya / Gupta, Pulkit / Shanmugam, Mala

    Frontiers in oncology

    2022  Volume 12, Page(s) 1000106

    Abstract: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of antibody producing plasma cells. Despite the use of next generation proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and immunotherapy, the ... ...

    Abstract Multiple myeloma (MM) is a plasma cell dyscrasia characterized by the clonal proliferation of antibody producing plasma cells. Despite the use of next generation proteasome inhibitors (PI), immunomodulatory agents (IMiDs) and immunotherapy, the development of therapy refractory disease is common, with approximately 20% of MM patients succumbing to aggressive treatment-refractory disease within 2 years of diagnosis. A large emphasis is placed on understanding inter/intra-tumoral genetic, epigenetic and transcriptomic changes contributing to relapsed/refractory disease, however, the contribution of cellular metabolism and intrinsic/extrinsic metabolites to therapy sensitivity and resistance mechanisms is less well understood. Cancer cells depend on specific metabolites for bioenergetics, duplication of biomass and redox homeostasis for growth, proliferation, and survival. Cancer therapy, importantly, largely relies on targeting cellular growth, proliferation, and survival. Thus, understanding the metabolic changes intersecting with a drug's mechanism of action can inform us of methods to elicit deeper responses and prevent acquired resistance. Knowledge of the Warburg effect and elevated aerobic glycolysis in cancer cells, including MM, has allowed us to capitalize on this phenomenon for diagnostics and prognostics. The demonstration that mitochondria play critical roles in cancer development, progression, and therapy sensitivity despite the inherent preference of cancer cells to engage aerobic glycolysis has re-invigorated deeper inquiry into how mitochondrial metabolism regulates tumor biology and therapy efficacy. Mitochondria are the sole source for coupled respiration mediated ATP synthesis and a key source for the anabolic synthesis of amino acids and reducing equivalents. Beyond their core metabolic activities, mitochondria facilitate apoptotic cell death, impact the activation of the cytosolic integrated response to stress, and through nuclear and cytosolic retrograde crosstalk maintain cell fitness and survival. Here, we hope to shed light on key mitochondrial functions that shape MM development and therapy sensitivity.
    Language English
    Publishing date 2022-09-16
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2022.1000106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Stromal Support of Metabolic Function through Mitochondrial Transfer in Multiple Myeloma.

    Boise, Lawrence H / Shanmugam, Mala

    Cancer research

    2019  Volume 79, Issue 9, Page(s) 2102–2103

    Abstract: Marlein and colleagues demonstrate in multiple myeloma, bone marrow stromal cells transfer mitochondria to myeloma cells to increase cellular respiration, resulting in increased proliferation. The intercellular transfer occurs through the formation of ... ...

    Abstract Marlein and colleagues demonstrate in multiple myeloma, bone marrow stromal cells transfer mitochondria to myeloma cells to increase cellular respiration, resulting in increased proliferation. The intercellular transfer occurs through the formation of tunneling nanotubes that connect the myeloma cell to the stromal cell and is dependent on surface CD38 expression on myeloma cells. CD38 is an important therapeutic target in myeloma, therefore, regulation of myeloma metabolism may play a role in the activity of this therapeutic approach. The study reinforces the importance of intercellular interactions in the tumor microenvironment and sheds new light on the control of metabolism in myeloma.
    MeSH term(s) Humans ; Mesenchymal Stem Cells ; Mitochondria ; Multiple Myeloma ; Stromal Cells ; Tumor Microenvironment
    Language English
    Publishing date 2019-04-28
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 1432-1
    ISSN 1538-7445 ; 0008-5472
    ISSN (online) 1538-7445
    ISSN 0008-5472
    DOI 10.1158/0008-5472.CAN-19-0500
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Bisbiguanide analogs induce mitochondrial stress to inhibit lung cancer cell invasion.

    Knippler, Christina M / Arnst, Jamie L / Robinson, Isaac E / Matsuk, Veronika / Khatib, Tala O / Harvey, R Donald / Shanmugam, Mala / Mouw, Janna K / Fu, Haian / Ganesh, Thota / Marcus, Adam I

    iScience

    2024  Volume 27, Issue 4, Page(s) 109591

    Abstract: Targeting cancer metabolism to limit cellular energy and metabolite production is an attractive therapeutic approach. Here, we developed analogs of the bisbiguanide, alexidine, to target lung cancer cell metabolism and assess a structure-activity ... ...

    Abstract Targeting cancer metabolism to limit cellular energy and metabolite production is an attractive therapeutic approach. Here, we developed analogs of the bisbiguanide, alexidine, to target lung cancer cell metabolism and assess a structure-activity relationship (SAR). The SAR led to the identification of two analogs, AX-4 and AX-7, that limit cell growth via G1/G0 cell-cycle arrest and are tolerated
    Language English
    Publishing date 2024-03-27
    Publishing country United States
    Document type Journal Article
    ISSN 2589-0042
    ISSN (online) 2589-0042
    DOI 10.1016/j.isci.2024.109591
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Targeting cancer metabolism through synthetic lethality-based combinatorial treatment strategies.

    Bajpai, Richa / Shanmugam, Mala

    Current opinion in oncology

    2018  Volume 30, Issue 5, Page(s) 338–344

    Abstract: Purpose of review: Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials. The present review highlights the latest strategies to target glucose and ... ...

    Abstract Purpose of review: Targeting cancer metabolism for therapy has received much attention over the last decade with various small molecule inhibitors entering clinical trials. The present review highlights the latest strategies to target glucose and glutamine metabolism for cancer therapy with a particular emphasis on novel combinatorial treatment approaches.
    Recent findings: Inhibitors of glucose, lactate, and glutamine transport and the ensuing metabolism are in preclinical to clinical trial stages of investigation. Recent advances in our understanding of cell-intrinsic and cell-extrinsic factors that dictate dependence on these targets have informed the development of rational, synthetic lethality-based strategies to exploit these metabolic vulnerabilities.
    Summary: Cancer cells exhibit a number of metabolic alterations with functional consequences beyond that of sustaining cellular energetics and biosynthesis. Elucidating context-specific metabolic dependencies and their connections to oncogenic signaling and epigenetic programs in tumor cells represents a promising approach to identify new metabolic drug targets for cancer therapy.
    MeSH term(s) Amino Acid Transport System ASC/antagonists & inhibitors ; Amino Acid Transport System ASC/metabolism ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Trials, Phase I as Topic ; Glucose/metabolism ; Glucose Transport Proteins, Facilitative/antagonists & inhibitors ; Glucose Transport Proteins, Facilitative/metabolism ; Glutaminase/antagonists & inhibitors ; Glutaminase/metabolism ; Glutamine/metabolism ; Humans ; Lactic Acid/metabolism ; Minor Histocompatibility Antigens/metabolism ; Molecular Targeted Therapy ; Monocarboxylic Acid Transporters/antagonists & inhibitors ; Monocarboxylic Acid Transporters/metabolism ; Neoplasms/drug therapy ; Neoplasms/metabolism ; Pyruvate Dehydrogenase Complex/antagonists & inhibitors ; Pyruvate Dehydrogenase Complex/metabolism
    Chemical Substances Amino Acid Transport System ASC ; Glucose Transport Proteins, Facilitative ; Minor Histocompatibility Antigens ; Monocarboxylic Acid Transporters ; Pyruvate Dehydrogenase Complex ; SLC1A5 protein, human ; Glutamine (0RH81L854J) ; Lactic Acid (33X04XA5AT) ; GLS protein, human (EC 3.5.1.2) ; Glutaminase (EC 3.5.1.2) ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2018-06-03
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Review
    ZDB-ID 1049384-0
    ISSN 1531-703X ; 1040-8746
    ISSN (online) 1531-703X
    ISSN 1040-8746
    DOI 10.1097/CCO.0000000000000467
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Cancer Metabolism and the Evasion of Apoptotic Cell Death.

    Sharma, Aditi / Boise, Lawrence H / Shanmugam, Mala

    Cancers

    2019  Volume 11, Issue 8

    Abstract: Cellular growth and proliferation depend upon the acquisition and synthesis of specific metabolites. These metabolites fuel the bioenergy, biosynthesis, and redox potential required for duplication of cellular biomass. Multicellular organisms maintain ... ...

    Abstract Cellular growth and proliferation depend upon the acquisition and synthesis of specific metabolites. These metabolites fuel the bioenergy, biosynthesis, and redox potential required for duplication of cellular biomass. Multicellular organisms maintain tissue homeostasis by balancing signals promoting proliferation and removal of cells via apoptosis. While apoptosis is in itself an energy dependent process activated by intrinsic and extrinsic signals, whether specific nutrient acquisition (elevated or suppressed) and their metabolism regulates apoptosis is less well investigated. Normal cellular metabolism is regulated by lineage specific intrinsic features and microenvironment driven extrinsic features. In the context of cancer, genetic abnormalities, unconventional microenvironments and/or therapy engage constitutive pro-survival signaling to re-program and rewire metabolism to maintain survival, growth, and proliferation. It thus becomes particularly relevant to understand whether altered nutrient acquisition and metabolism in cancer can also contribute to the evasion of apoptosis and consequently therapy resistance. Our review attempts to dissect a causal relationship between two cancer hallmarks, i.e., deregulated cellular energetics and the evasion of programmed cell death with primary focus on the intrinsic pathway of apoptosis.
    Language English
    Publishing date 2019-08-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers11081144
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.

    Chandrasekaran, Sanjay / Funk, Christopher Ronald / Kleber, Troy / Paulos, Chrystal M / Shanmugam, Mala / Waller, Edmund K

    Frontiers in immunology

    2021  Volume 12, Page(s) 718621

    Abstract: PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell ... ...

    Abstract PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition
    MeSH term(s) Animals ; Biomarkers ; Class I Phosphatidylinositol 3-Kinases/antagonists & inhibitors ; Class I Phosphatidylinositol 3-Kinases/immunology ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Class Ib Phosphatidylinositol 3-Kinase/immunology ; Class Ib Phosphatidylinositol 3-Kinase/metabolism ; Disease Management ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Immunotherapy, Adoptive ; Lymphocyte Activation/immunology ; Molecular Targeted Therapy ; Signal Transduction ; T-Lymphocyte Subsets/immunology ; T-Lymphocyte Subsets/metabolism ; Translational Research, Biomedical
    Chemical Substances Biomarkers ; Immune Checkpoint Inhibitors ; Class I Phosphatidylinositol 3-Kinases (EC 2.7.1.137) ; Class Ib Phosphatidylinositol 3-Kinase (EC 2.7.1.137) ; PIK3CD protein, human (EC 2.7.1.137) ; PIK3CG protein, human (EC 2.7.1.137)
    Language English
    Publishing date 2021-08-26
    Publishing country Switzerland
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2021.718621
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Engineering Improved CAR T Cell Products with A Multi-Cytokine Particle Platform for Hematologic and Solid Tumors.

    Lin, Heather K / Uricoli, Biaggio / Freeman, Ruby / Hossian, Akm Nawshad / He, Zhulin / Anderson, Ji Young L / Neffling, Milla / Legier, Jonathan M / Blake, Dejah A / Doxie, Deon B / Nair, Remya / Koff, Jean L / Dhodapkar, Kavita M / Shanmugam, Mala / Dreaden, Erik C / Rafiq, Sarwish

    Advanced healthcare materials

    2024  , Page(s) e2302425

    Abstract: Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated with CAR T cell products enriched with T ... ...

    Abstract Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieves a durable complete response (dCR). DCR has been correlated with CAR T cell products enriched with T cells memory phenotypes. Therefore, reagents that consistently promote memory phenotypes during the manufacturing of CAR T cells have the potential to significantly improve clinical outcomes. A novel modular multi-cytokine particle (MCP) platform is developed that combines the signals necessary for activation, costimulation, and cytokine support into a single "all-in-one" stimulation reagent for CAR T cell manufacturing. This platform allows for the assembly and screening of compositionally diverse MCP libraries to identify formulations tailored to promote specific phenotypes with a high degree of flexibility. The approach is leveraged to identify unique MCP formulations that manufacture CAR T cell products from diffuse large B cell patients   with increased proportions of memory-like phenotypes MCP-manufactured CAR T cells demonstrate superior anti-tumor efficacy in mouse models of lymphoma and ovarian cancer through enhanced persistence. These findings serve as a proof-of-principle of the powerful utility of the MCP platform to identify "all-in-one" stimulation reagents that can improve the effectiveness of cell therapy products through optimal manufacturing.
    Language English
    Publishing date 2024-01-21
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2649576-4
    ISSN 2192-2659 ; 2192-2640
    ISSN (online) 2192-2659
    ISSN 2192-2640
    DOI 10.1002/adhm.202302425
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma.

    Nair, Remya / Subramaniam, Vimal / Barwick, Benjamin G / Gupta, Vikas A / Matulis, Shannon M / Lonial, Sagar / Boise, Lawrence H / Nooka, Ajay K / Muthumalaiappan, Kuzhali / Shanmugam, Mala

    Haematologica

    2022  Volume 107, Issue 9, Page(s) 2226–2231

    MeSH term(s) Adrenergic Agents ; Hematopoietic Stem Cells ; Humans ; Multiple Myeloma/therapy
    Chemical Substances Adrenergic Agents
    Language English
    Publishing date 2022-09-01
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.280907
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.

    Findlay, Steven / Nair, Remya / Merrill, Ronald A / Kaiser, Zafir / Cajelot, Alexandre / Aryanpour, Zahra / Heath, John / St-Louis, Catherine / Papadopoli, David / Topisirovic, Ivan / St-Pierre, Julie / Sebag, Michael / Kesarwala, Aparna H / Hulea, Laura / Taylor, Eric B / Shanmugam, Mala / Orthwein, Alexandre

    Blood advances

    2023  Volume 7, Issue 14, Page(s) 3485–3500

    Abstract: Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-producing plasma B cells. Proteasome inhibitors, including the US Food and Drug Administration-approved bortezomib (BTZ) and carfilzomib (CFZ), are frequently used for the ... ...

    Abstract Multiple myeloma (MM) is a hematological malignancy that emerges from antibody-producing plasma B cells. Proteasome inhibitors, including the US Food and Drug Administration-approved bortezomib (BTZ) and carfilzomib (CFZ), are frequently used for the treatment of patients with MM. Nevertheless, a significant proportion of patients with MM are refractory or develop resistance to this class of inhibitors, which represents a significant challenge in the clinic. Thus, identifying factors that determine the potency of proteasome inhibitors in MM is of paramount importance to bolster their efficacy in the clinic. Using genome-wide CRISPR-based screening, we identified a subunit of the mitochondrial pyruvate carrier (MPC) complex, MPC1, as a common modulator of BTZ response in 2 distinct human MM cell lines in vitro. We noticed that CRISPR-mediated deletion or pharmacological inhibition of the MPC complex enhanced BTZ/CFZ-induced MM cell death with minimal impact on cell cycle progression. In fact, targeting the MPC complex compromised the bioenergetic capacity of MM cells, which is accompanied by reduced proteasomal activity, thereby exacerbating BTZ-induced cytotoxicity in vitro. Importantly, we observed that the RNA expression levels of several regulators of pyruvate metabolism were altered in advanced stages of MM for which they correlated with poor patient prognosis. Collectively, this study highlights the importance of the MPC complex for the survival of MM cells and their responses to proteasome inhibitors. These findings establish mitochondrial pyruvate metabolism as a potential target for the treatment of MM and an unappreciated strategy to increase the efficacy of proteasome inhibitors in the clinic.
    MeSH term(s) United States ; Humans ; Proteasome Inhibitors/pharmacology ; Proteasome Inhibitors/therapeutic use ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Antineoplastic Agents/therapeutic use ; Monocarboxylic Acid Transporters/therapeutic use ; Bortezomib/pharmacology ; Bortezomib/therapeutic use ; Pyruvates/therapeutic use
    Chemical Substances Proteasome Inhibitors ; Antineoplastic Agents ; Monocarboxylic Acid Transporters ; Bortezomib (69G8BD63PP) ; Pyruvates
    Language English
    Publishing date 2023-03-31
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2022008345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Venetoclax ex vivo functional profiling predicts improved progression-free survival.

    Gupta, Vikas A / Matulis, Shannon M / Barwick, Benjamin G / Bog, R Devin / Shebelut, Conrad W / Shanmugam, Mala / Neri, Paola / Bahlis, Nizar J / Dhodapkar, Madhav V / Heffner, Leonard T / Hofmeister, Craig C / Joseph, Nisha S / Lonial, Sagar / Kaufman, Jonathan L / Jaye, David L / Nooka, Ajay K / Boise, Lawrence H

    Blood cancer journal

    2022  Volume 12, Issue 8, Page(s) 115

    MeSH term(s) Antineoplastic Combined Chemotherapy Protocols ; Bridged Bicyclo Compounds, Heterocyclic/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Humans ; Progression-Free Survival ; Proto-Oncogene Proteins c-bcl-2 ; Sulfonamides/therapeutic use
    Chemical Substances Bridged Bicyclo Compounds, Heterocyclic ; Proto-Oncogene Proteins c-bcl-2 ; Sulfonamides ; venetoclax (N54AIC43PW)
    Language English
    Publishing date 2022-08-04
    Publishing country United States
    Document type Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2600560-8
    ISSN 2044-5385 ; 2044-5385
    ISSN (online) 2044-5385
    ISSN 2044-5385
    DOI 10.1038/s41408-022-00710-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top